Skip to the page

Data / Drug companies / Naari Pte Limited

Naari Pte Limited: 12 products in the FDA NDC directory, labeler code 79929

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Naari Pte Limited (labeler code 79929) lists 12 products in the FDA National Drug Code Directory, covering 9 finished drugs by generic name. By type: 11 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on June 11, 2024.

The request: Watch Naari Pte Limited (FDA labeler code 79929): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
79929
Products in commercial distribution
12
Packages
12
Finished drugs by generic name
9
Prescription products
11
Over the counter products
1
Flagged as original packager
12 of 12 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
December 31, 2022
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)12100%

Products by type

TypeProductsShare
Prescription drugs1191.7%
Over the counter drugs18.3%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Kit975%
Tablet325%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Estradiol and norethindrone acetate79929-012TabletGeneric drugs (ANDA)June 11, 2024
Affodel79929-015TabletGeneric drugs (ANDA)May 31, 2024
Norgestimate and ethinyl estradiol79929-008KitGeneric drugs (ANDA)March 31, 2024
Desogestrel and ethinyl estradiol79929-006KitGeneric drugs (ANDA)March 31, 2024
Levonorgestrel and Ethinyl Estradiol79929-004KitGeneric drugs (ANDA)March 31, 2024
Desogestrel and ethinyl estradiol and ethinyl estradiol79929-020KitGeneric drugs (ANDA)April 5, 2023
Drospirenone and ethinyl estradiol79929-019KitGeneric drugs (ANDA)April 5, 2023
Levonorgestrel79929-016TabletGeneric drugs (ANDA)February 16, 2023
Norgestimate and ethinyl estradiol79929-009KitGeneric drugs (ANDA)December 31, 2022
Norethindrone and ethinyl estradiol79929-007KitGeneric drugs (ANDA)December 31, 2022
Norethindrone and ethinyl estradiol and ferrous fumarate79929-005KitGeneric drugs (ANDA)December 31, 2022
Levonorgestrel and Ethinyl Estradiol79929-003KitGeneric drugs (ANDA)December 31, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.